Gilead agrees to buy Kite Pharma, leaping into CAR-T cancer therapy – STAT
STAT |
Gilead agrees to buy Kite Pharma, leaping into CAR–T cancer therapy
STAT With the Kite deal, Gilead becomes a player in a new type of blockbuster cancer treatment in which a patient's own immune cells are re-engineered to recognize and kill cancer cells — a technology known as CAR–T. Kite's lead therapy, known as axi-cel, … Gilead to Buy Kite for Promising Cancer Therapies in $12 Billion Deal Gilead to buy Kite Pharma for about $12 billion Gilead Sciences to Acquire Israeli Cancer Curing Kite Pharma for $11.9 Billion |
